Pre‐clinical efficacy of PU‐H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma

Molecular Oncology - Tập 8 - Trang 323-336 - 2014
Srikanth R. Ambati1, Eloisi Caldas Lopes2, Kohji Kosugi2, Ullas Mony2, Ahmet Zehir2, Smit K. Shah3, Tony Taldone3, Andre L. Moreira4, Paul A. Meyers1, Gabriela Chiosis3, Malcolm A.S. Moore2
1Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
2Department of Cell Biology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA
3Department of Molecular Pharmacology & Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA
4Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.

Tóm tắt

Ewing sarcoma is characterized by multiple deregulated pathways that mediate cell survival and proliferation. Heat shock protein 90 (HSP90) is a critical component of the multi‐chaperone complexes that regulate the disposition and activity of a large number of proteins involved in cell‐signaling systems. We tested the efficacy of PU‐H71, a novel HSP90 inhibitor in Ewing sarcoma cell lines, primary samples, benign mesenchymal stromal cells and hematopoietic stem cells. We performed cell cycle analysis, clonogenic assay, immunoblot analysis and reverse phase protein array in Ewing cell lines and in vivo experiments in NSG and nude mice using the A673 cell line. We noted a significant therapeutic window in the activity of PU‐H71 against Ewing cell lines and benign cells. PU‐H71 treatment resulted in G2/M phase arrest. Exposure to PU‐H71 resulted in depletion of critical proteins including AKT, pERK, RAF‐1, c‐MYC, c‐KIT, IGF1R, hTERT and EWS‐FLI1 in Ewing cell lines. Our results indicated that Ewing sarcoma tumor growth and the metastatic burden were significantly reduced in the mice injected with PU‐H71 compared to the control mice. We also investigated the effects of bortezomib, a proteasome inhibitor, alone and in combination with PU‐H71 in Ewing sarcoma. Combination index (CI)‐Fa plots and normalized isobolograms indicated synergism between PU‐H71 and bortezomib. Ewing sarcoma xenografts were significantly inhibited when mice were treated with the combination compared to vehicle or either drug alone. This provides a strong rationale for clinical evaluation of PU‐H71 alone and in combination with bortezomib in Ewing sarcoma.

Tài liệu tham khảo

10.1002/ijc.20611 10.1158/1078-0432.CCR-06-1892 10.1128/MCB.14.5.3230 10.1002/ijc.11576 10.1073/pnas.93.16.8379 10.1073/pnas.0903392106 10.1038/nm.2059 10.1158/0008-5472.CAN-09-1947 2007 ComboSyn Inc. Paramus NJ. T.-C. Chou N. Martin CompuSyn Software for Drug Combinations and for General Dose-Effect Analysis and User's Guide 10.1016/j.ccr.2012.04.023 10.1158/1078-0432.CCR-09-2261 10.1038/nprot.2006.339 10.1097/01.blo.0000141385.77071.8d 10.1038/onc.2010.640 10.1056/NEJMoa020890 10.1021/jm0508078 10.1007/s12014-010-9055-y 10.1371/journal.pone.0005415 10.1002/ijc.10820 10.1016/S0002-9440(10)64850-X 10.1097/CAD.0b013e3282ef532d Lin P.P., 1999, Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma, Cancer Res., 59, 1428 10.1016/S0014-5793(01)02130-5 10.1002/cncr.20968 10.1158/0008-5472.CAN-07-3074 10.1016/S0165-4608(02)00670-2 10.1172/JCI42442 10.1002/ijc.24660 10.1002/pbc.21233 10.1182/blood-2005-03-1158 10.1158/1078-0432.CCR-09-2886 10.1038/nchembio.670 Nimmanapalli R., 2001, Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts, Cancer Res., 61, 1799 10.1038/sj.onc.1208060 10.1002/gcc.20717 10.1200/JCO.2010.34.0000 10.1186/1471-2407-12-233 RCoreTeam n.d. R: a Language and Environment for Statistical Computing 2012 ed. R Foundation for Statistical Computing Vienna Austria. 10.1182/blood-2010-04-278853 10.1002/cyto.990130216 Scotlandi K., 1998, Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice, Cancer Res., 58, 4127 Scotlandi K., 1996, Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target, Cancer Res., 56, 4570 10.1038/sj.onc.1203811 10.1200/JCO.2009.27.0421 10.1158/0008-5472.CAN-09-1993 Takahashi A., 2003, EWS/ETS fusions activate telomerase in Ewing's tumors, Cancer Res., 63, 8338 10.1002/gcc.20074 10.1002/(SICI)1097-0320(19960601)24:2<131::AID-CYTO5>3.0.CO;2-M 10.1158/1078-0432.CCR-06-2270 10.1038/nrc1716
Thông tin
Thông tin xuất bản

Molecular Oncology

Tập 8

323-336

Thông tin tác giả